Red X iconGreen tick iconYellow tick icon
Clocktower.Wednesday, 1 August 2018

Max Berry image
Dr Max Berry

A University of Otago researcher has received funding from the Neurological Foundation of New Zealand to investigate a new therapy which could potentially prevent disorders developing in children born prematurely.

Senior Lecturer in the Department of Paediatrics and Child Health at the University of Otago, Wellington, Dr Max Berry, has been awarded $180,120 by the foundation to investigate the use of neurosteroid analogue therapy which could potentially prevent behavioural and neurodevelopmental disorders developing in children and adolescents who are born prematurely.

Dr Berry's research interest focuses on investigating the impact of preterm birth on the person's long-term health.

“Despite all best efforts prem babies still have higher rates of learning and developmental problems compared to children born at full term,” Dr Berry explains.

“We want to try and reduce this gap so that children thrive, irrespective of their gestational age.”

Research Dr Berry has undertaken previously shows that hormones a baby would have been exposed to had it stayed in the womb until full term, help with brain development. When babies are born early, they miss out on these vital hormones.

“We are trying to find ways to replace the beneficial effects of these hormones by giving a replacement therapy in the time between preterm birth and the due date.”

Dr Berry says she and her team are “absolutely delighted” to have the support of the Neurological Foundation to help them carry out the research.

“It's so important that these preterm babies don't suffer health and wellbeing disadvantage through the rest of their lives – we want to develop new therapies so this on-going health disparity is prevented.”

Dr Berry is one of five University of Otago researchers who received some of the $1.5 million in funding recently awarded by the Neurological Foundation.

Professor Cliff Abraham from Otago's Brain Health Research Centre and the Department of Psychology received $240,857 to continue his investigations into the birth of new nerve cells in the adult brain. Dr Rebekah Blakemore from the Department of Medicine at the University of Otago, Christchurch, received $168,190 for her investigations into Parkinson's disease.

Senior Lecturer in clinical pharmacy Dr Ailsa McGregor, who works both within the School of Pharmacy and the Brain Health Research Centre, received $197,195 for her research focusing on pharmacological enhancement of motor recovery after stroke; while Professor David Bilkey from the Department of Psychology received $14,925 for his investigations into schizophrenia.

Chief executive of the Neurological Foundation Rich Easton says he is pleased to recently confirm the approval of nearly $1.5 million in funding for projects, travel grants and a fellowship.

“This was one of our largest ever grant rounds, with the funds going to support research into diseases and disorders of the brain, offering hope to 1 in 5 New Zealanders impacted by more than 1000 different conditions.”

Further details of the research being carried out by University of Otago researchers is below:

Dr Max Berry: Neurosteroid analogue therapy to prevent behavioural and neurodevelopmental disorders in children and adolescents born preterm

Altered white matter in the brain plays a major role in the development of behavioural and neurodevelopmental disabilities following premature birth. We have shown that placental supply of steroids that promote brain development are prematurely reduced following preterm birth, impairing white matter development, and leading to perturbed behaviour in the preterm babies as they move through into adolescence. Our preliminary data suggests that restoring the action of these steroids protects the preterm brain and results in normal myelination and behaviour. Thus, this research proposal aims to build on this data to optimise our novel therapy to ameliorate the adverse effects of premature birth on brain development.

Prof Cliff Abraham image
Professor Cliff Abraham

Professor Cliff Abraham
Characterising and enhancing the functionality of adult-born hippocampal neurons

The prevalence of dementia is increasing at an alarming rate. Finding ways to reduce memory impairments in dementia and other memory disorders is thus an urgent need in neurology. The hippocampus is a brain structure critical for memory, but is commonly affected in neurological disorders. This structure is unique in being able to generate new neurons throughout life. In this project, we aim to understand the functional capability of these adult-born cells and how it changes across their life-course, using genetic and imaging technologies. We will also determine whether environmental interventions can increase the functionality of this key cell type. These findings may help identify how cognitive stimulation and exercise help stave off cognitive decline in disorders such as Alzheimer's disease, in which neurogenesis and memory are impaired.

Rebekah Blakemore image
Dr Rebekah Blakemore

Dr Rebekah Blakemore
Understanding the role of dopamine in stress-induced motor deficits in Parkinson's disease

We have recently demonstrated that emotional stress can worsen the motor impairments of individuals with Parkinson's disease. These findings are consistent with previous studies in animal models of Parkinson's however, it remains unclear how stress disrupts the control of movement and alters dopamine in the brain. This study will build on our earlier research by investigating changes in brain activity (using functional brain imaging) that are associated with impaired movement during stress in people with Parkinson's. Understanding the impact of acute stress on movement control may inform development of emotion-movement interventions to improve motor function in people with Parkinson's disease.

Ailsa McGregor image
Dr Ailsa McGregor

Dr Ailsa McGregor
Investigating the anti-inflammatory effects of novel curcumin analogues in stroke

The naturally occurring polyphenol, curcumin has been intensively investigated as a potential therapy for malignant and inflammatory diseases. More recently, curcumin has been shown to prevent brain damage during stroke. We will investigate whether a series of novel and highly potent curcumin analogues can also reduce brain inflammation and improve functional recovery in an experimental stroke model. This work will provide supporting evidence to develop a pharmacological therapy which could easily translate to the clinical setting. This approach has significant implications for surviving stroke patients who arrive late to hospital and are not suitable for clot-buster therapy.

David bilkey image
Professor David Bilkey

Professor David Bilkey
Hippocampal dysfunction underlying disrupted future thinking in neurological disorders

Schizophrenia is a disorder of brain function, characterised by a number of symptoms, including deficits in decision-making. We hypothesise that these deficits are a result of a disturbance in the brain activity in the hippocampus that underlies our ability to simulate the future. We propose to test this hypothesis by determining whether characteristic neuron burst firing events that are involved in mental simulations of the future are disordered in a model of the disease. This project can potentially explain some of the executive function deficits observed in schizophrenia and also provide a preclinical biomarker that could be targeted for therapy.

For further information, contact:

Dr Max Berry
Senior Lecturer, Department of Paediatrics and Child Health
Tel 04 385 5999

Liane Topham-Kindley
Senior Communications Adviser
Tel 03 479 9065
Mob 021 279 9065

A list of Otago experts available for media comment is available elsewhere on this website.

Electronic addresses (including email accounts, instant messaging services, or telephone accounts) published on this page are for the sole purpose of contact with the individuals concerned, in their capacity as officers, employees or students of the University of Otago, or their respective organisation. Publication of any such electronic address is not to be taken as consent to receive unsolicited commercial electronic messages by the address holder.
Back to top